What is Harrow?
Harrow, Inc. is a specialized eyecare pharmaceutical company dedicated to the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company's portfolio includes a range of solutions, such as ImprimisRx, which are compounded medications tailored for ophthalmology. Harrow also offers various ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, alongside established products like MAXITROL eye drops and ILEVRO/NEVANAC for post-cataract surgery pain and inflammation. Their offerings extend to antibiotic eye drops like VIGAMOX, steroid eye drops such as MAXIDEX and FLAREX for inflammatory conditions, and TRIESENCE, a steroid injection for treating ophthalmic diseases. Additionally, Harrow provides NATACYN for fungal eye infections and TOBRADEX ST, VERKAZIA, and FRESHKOTE preservative-free lubricant eye drops. Headquartered in Nashville, Tennessee, Harrow is strategically positioned to address critical needs within the eyecare market.
How much funding has Harrow raised?
Harrow has raised a total of $113.5M across 2 funding rounds:
Debt
$1M
Debt
$112.5M
Debt (2020): $1M with participation from PPP
Debt (2023): $112.5M led by Oaktree
Key Investors in Harrow
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments. The company is recognized for its opportunistic, value-oriented, and risk-controlled approach to investing across credit, equity, and real estate markets. Oaktree Capital Management partners with clients worldwide to identify investment opportunities that balance potential returns with disciplined risk management. With a team of experienced professionals and a presence in multiple cities around the globe, the firm combines deep market insight with a long-term perspective to deliver consistent, strategic outcomes for its investors. Oaktree is also committed to maintaining integrity and transparency in its operations, actively safeguarding against fraud and ensuring secure and responsible engagement with clients and stakeholders.
PPP
Public-Private Partnership
What's next for Harrow?
With the recent major strategic investment, Harrow is poised for significant expansion and innovation. The company's focus on developing and commercializing advanced ophthalmic pharmaceutical products, coupled with its diverse product pipeline, suggests a strategic push towards scaling operations and potentially broadening its market reach. This capital backing will likely fuel further research and development initiatives, enhance manufacturing capabilities, and support expanded commercialization efforts for its existing and pipeline products. The company's trajectory indicates a strong emphasis on solidifying its position as a key player in the eyecare pharmaceutical industry, driven by a commitment to addressing unmet patient needs through scientific advancement and strategic partnerships.
See full Harrow company page
